(2023). Proton pump inhibitors and the risk of inflammatory bowel disease: population-based cohort study. Gut. http://doi.org/10.1136/gutjnl-2022-328866
. D. Abrahami
First name
D.
Last name
Abrahami
(2022). Sodium-Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study. Diabetes Care. http://doi.org/10.2337/dc22-1174
. (2018). Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes. Epidemiology. http://doi.org/10.1097/ede.0000000000000891
. (2018). Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. Bmj. http://doi.org/10.1136/bmj.k4880
. (2018). Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes. Epidemiology. http://doi.org/10.1097/ede.0000000000000793
. (2018). Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. Bmj. http://doi.org/10.1136/bmj.k872
. (2019). Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes. Diabetes Care. http://doi.org/10.2337/dc19-0849
. (2020). Trends in acid suppressant drug prescriptions in primary care in the UK: a population-based cross-sectional study. BMJ Open. http://doi.org/10.1136/bmjopen-2020-041529
. (2020). The Association between Oral Anticoagulants and Cancer Incidence among Individuals with Nonvalvular Atrial Fibrillation. Thromb Haemost. http://doi.org/10.1055/s-0040-1714213
. (2021). Proton pump inhibitors and risk of colorectal cancer. Gut. http://doi.org/10.1136/gutjnl-2021-325096
.